These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 8781766

  • 1. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 2. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [Abstract] [Full Text] [Related]

  • 3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 4. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 5. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec 26; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 6. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW.
    J Clin Endocrinol Metab; 1998 Sep 26; 83(9):3169-76. PubMed ID: 9745421
    [Abstract] [Full Text] [Related]

  • 7. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabetes Care; 1996 Feb 26; 19(2):151-6. PubMed ID: 8718436
    [Abstract] [Full Text] [Related]

  • 8. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM.
    Diabetes Care; 1997 Feb 26; 20(2):188-93. PubMed ID: 9118772
    [Abstract] [Full Text] [Related]

  • 9. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW.
    Diabetes Care; 1998 Sep 26; 21(9):1462-9. PubMed ID: 9727892
    [Abstract] [Full Text] [Related]

  • 10. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
    Ebeling P, Teppo AM, Koistinen HA, Viikari J, Rönnemaa T, Nissén M, Bergkulla S, Salmela P, Saltevo J, Koivisto VA.
    Diabetologia; 1999 Dec 26; 42(12):1433-8. PubMed ID: 10651262
    [Abstract] [Full Text] [Related]

  • 11. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
    Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT.
    Diabetes Res Clin Pract; 2002 Nov 26; 58(2):87-96. PubMed ID: 12213349
    [Abstract] [Full Text] [Related]

  • 12. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.
    Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H.
    Diabet Med; 1994 Nov 26; 11(7):685-91. PubMed ID: 7955995
    [Abstract] [Full Text] [Related]

  • 13. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 14. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
    Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Diaz RA, Salinas-Orozco S, Chavira-López IJ, Sánchez-Reyes L, Torres-Acosta EM, Tamez R, López A, Guillén LE, Cesarman G.
    Metabolism; 2002 Jan 01; 51(1):44-51. PubMed ID: 11782871
    [Abstract] [Full Text] [Related]

  • 15. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.
    Young MA, Eckland DJ, Eastmond R, Lettis S.
    Ann Med; 1998 Apr 01; 30(2):206-12. PubMed ID: 9667800
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.
    Diabetes Care; 2002 Mar 01; 25(3):542-9. PubMed ID: 11874944
    [Abstract] [Full Text] [Related]

  • 17. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
    Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW.
    Diabetes; 1997 Mar 01; 46(3):433-9. PubMed ID: 9032099
    [Abstract] [Full Text] [Related]

  • 18. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA.
    Diabetes; 1996 Nov 01; 45(11):1572-9. PubMed ID: 8866563
    [Abstract] [Full Text] [Related]

  • 19. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
    Foot EA, Eastmond R.
    Diabetes Res Clin Pract; 1997 Oct 01; 38(1):41-51. PubMed ID: 9347245
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.